A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
Condition: Colitis, Ulcerative Interventions: Drug: GLPG3970; Drug: Placebo Sponsor: Galapagos NV Recruiting
Serious and severe adverse events, as well as higher rates of discontinuation due to treatment-related adverse events, were more common in the placebo group.Medscape Medical News
J Clin Biochem Nutr. 2021 Nov;69(3):265-271. doi: 10.3164/jcbn.20-189. Epub 2021 May 28.ABSTRACTInflammation is a primary risk factor for cancer. Epidemiological studies previously demonstrated that aspirin decreased the incidence of cancer and specifically reduced the risk of colorectal cancer. However, the number of animal studies that have confirmed the efficacy of aspirin remains limited. Therefore, the purpose of the present study was to investigate the mechanisms by which aspirin prevents colorectal cancer in mice. ICR mice were treated with azoxymethane and the ulcerative colitis inducer, dextran sodium sulfate, to ...
CONCLUSION: Tofacitinib demonstrated consistent safety up to 7.0 years. Data collected up to Month 36 support long-term efficacy beyond the 52-week maintenance study.PMID:34854095 | DOI:10.1111/apt.16712
Contributors : Felix Sommer ; Jacob Hamm ; Finn Hinrichsen ; Neha Mishra ; Philip RosenstielSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHexokinases (HK) catalyze the first step of glycolysis and thereby limit its pace. HK2 is highly expressed in the gut epithelium, plays a role in immune responses and is upregulated in inflammation and ulcerative colitis 1-3. Here, we examined the microbial regulation of HK2 and its impact on intestinal inflammation by generating mice lacking HK2 specifically in intestinal epithelial cells (Hk2 ∆IEC). Hk2∆IEC mice were less susceptible to acut...
Conclusion: CASP1, SERPINA1, and CCL2 are autophagy-related hub genes of active UC. And SERPINA1 may serve as a new pharmacological autophagy regulator of UC, which provides a new target for the use of small molecules targeting autophagy in the treatment of active UC.
CONCLUSIONS: After 3 months of conventional treatment there were no differences in fatigue severity in patients reaching deep remission compared with patients still having active disease. Fatigue was more pronounced in patients in deep remission than in healthy subjects, and was associated with subjective and not objective measures of disease activity. This indicates that other potent factors than inflammation influence fatigue in UC.PMID:34846950 | DOI:10.1080/00365521.2021.2007281
Title: What Is the Best Diet for Someone With Ulcerative Colitis?Category: Diseases and ConditionsCreated: 11/30/2021 12:00:00 AMLast Editorial Review: 11/30/2021 12:00:00 AM